PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
1.01%
Revenue growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.36%. Joel Greenblatt would verify if operating margins keep pace with this top-line surge.
-129.16%
Negative gross profit growth while Drug Manufacturers - Specialty & Generic median is 0.81%. Seth Klarman would suspect poor product pricing or inefficient production.
-2648.08%
Negative EBIT growth while Drug Manufacturers - Specialty & Generic median is 3.65%. Seth Klarman would check if external or internal factors caused the decline.
-2648.08%
Negative operating income growth while Drug Manufacturers - Specialty & Generic median is 6.07%. Seth Klarman would check if structural or cyclical issues are at play.
-1840.05%
Negative net income growth while Drug Manufacturers - Specialty & Generic median is 4.58%. Seth Klarman would investigate factors dragging net income down.
-1840.00%
Negative EPS growth while Drug Manufacturers - Specialty & Generic median is 7.14%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-1840.00%
Negative diluted EPS growth while Drug Manufacturers - Specialty & Generic median is 7.14%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
0.63%
Share growth above Drug Manufacturers - Specialty & Generic median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
0.63%
Diluted share growth above 2x Drug Manufacturers - Specialty & Generic median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
-163.79%
Negative OCF growth while Drug Manufacturers - Specialty & Generic median is 12.19%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-178.99%
Negative FCF growth while Drug Manufacturers - Specialty & Generic median is 16.20%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
297.40%
5Y revenue/share growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 17.23%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
-52.47%
Negative 3Y CAGR while Drug Manufacturers - Specialty & Generic median is 12.10%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
-297.77%
Negative 10Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-3403.96%
Negative 5Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
83.35%
3Y OCF/share growth > 1.5x Drug Manufacturers - Specialty & Generic median of 7.28%. Joel Greenblatt might see a recent competitive advantage translating into cash improvements.
-51280.40%
Negative 10Y net income/share CAGR vs. Drug Manufacturers - Specialty & Generic median of 20.59%. Seth Klarman might see a fundamental problem if peers maintain growth.
-2688.92%
Negative 5Y CAGR while Drug Manufacturers - Specialty & Generic median is 9.84%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-9959.44%
Negative 3Y CAGR while Drug Manufacturers - Specialty & Generic median is 9.89%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
6257.60%
Equity/share CAGR of 6257.60% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
29.59%
5Y equity/share CAGR of 29.59% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
-12.97%
Negative 3Y equity/share growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12.67%
AR shrinking while Drug Manufacturers - Specialty & Generic median grows. Seth Klarman sees potential advantage unless it signals declining demand.
-15.83%
Decreasing inventory while Drug Manufacturers - Specialty & Generic is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
-20.07%
Assets shrink while Drug Manufacturers - Specialty & Generic median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-24.48%
Negative BV/share change while Drug Manufacturers - Specialty & Generic median is -1.53%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-0.85%
Debt is shrinking while Drug Manufacturers - Specialty & Generic median is rising. Seth Klarman might see an advantage if growth remains possible.
3.64%
R&D growth of 3.64% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
-11.81%
SG&A decline while Drug Manufacturers - Specialty & Generic grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.